Evaxion Biotech A/S has developed a new proprietary artificial intelligence (AI) platform technology, Observ, to identify a new source of targets for personalized cancer therapy, potentially enabling treatment for patients with cold tumors, normally unresponsive to immunotherapy.
Ono Pharmaceutical Co. Ltd. has entered into a worldwide drug discovery collaboration agreement with Macomics Ltd. to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer.
Shuttle Pharmaceuticals Holdings Inc. has entered a research agreement with Georgetown University focused on the evaluation of the company's lead histone deacetylase 6 (HDAC6) inhibitor candidate, SP-2-225, evaluating the antitumor effect of the combination of SP-2-225 and radiation therapy in a syngeneic breast cancer model.
A research group at Washington University School of Medicine has released animal data showing restriction of tumor growth with a novel mRNA therapeutic delivered in nanoparticles based on Altamira Therapeutics Ltd.’s Semaphore delivery platform.
Coimmune Inc. has exercised its option to obtain an exclusive license to IL-18 armored chimeric antigen receptor (CAR) technology under a prior agreement with Memorial Sloan Kettering Cancer Center (MSK). The company plans to couple the technology with allogeneic cytokine induced killer (CIK) cells to launch the clinical development of CMN-008 (armored CAR-CIK cells), with CD19 as the initial target in B-cell malignancies.
Lift Biosciences Ltd. has released preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMANp) possesses both cytotoxic and immunomodulatory functionalities that could signal its potential to cure solid tumors. IMANp is generated from the hematopoietic stem cells of donors with exceptional anticancer innate immunity.
T cells do not have the last word in some breast cancers. According to a study from the University of Pittsburgh, the key to estrogen receptor positive (ER+) breast tumors are macrophages, not T cells, and targeting them could prevent immunotherapy failure in this type of cancer.
RSS
